Work productivity loss due to flares in patients with chronic gout
refractory to conventional therapy.
rheumatologists and managed care organization (MCO) pharmacy directors agree that the percentage of patients who reach target serum uric acid levels is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in chronic gout
KRYSTEXXA is a PEGylated uric acid specific enzyme, or uricase, that has been shown to statistically significantly reduce uric acid levels for many patients with refractory chronic gout
About half the patients with chronic gout
have significant impairment of renal function," said Dr.
The chronic gout
market, which encompasses urate-lowering and prophylactic anti-inflammatory therapies, will experience even faster growth at a CAGR of 18.
Infusion-Related Reactions with Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout
Refractory to Conventional Therapy - Baraf HSB, Yood RA, et al.
Pegloticase, a recombinant formulation of porcine uricase, has been approved for the treatment of chronic gout
in adults who are refractory to conventional treatments.
This drug is a selectively PEGylated enzyme (uricase) that degrades uric acid and has been shown to be safe and effective for the treatment of adults with refractory chronic gout
, who are unresponsive or allergic to other available treatments.
Currently, acute gout can be treated using NSAIDs, corticosteroids and Colcrys, while doctors can prescribe uricosurics sulphinpyrazone, benzbromarone or xanthine oxidase inhibitors to treat chronic gout
Sales of Therapies to Treat Chronic Gout
Will Double from $500 Million in 2011 to More Than $1 Billion in 2021, According to Findings from Decision Resources
48) Subsequently, both rilonacept and canakinmab have been studied in a variety of clinical settings, for both acute and chronic gout
and as gout prophylaxis during urate-lowering therapy.
Savient said it had received a so-called "complete response letter" from the FDA stating that the FDA "can not at this time approve" its application for the drug as a treatment for chronic gout